A phase II trial assessing feasibility of personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer

 

Trial Summary:

A randomised, open-label, phase II trial assessing standard first-line treatment with gemcitabine or personalised treatment based on the tumour molecular signature in patients with recurrent or metastatic pancreatic cancer.

Supported By:

Sydney Catalyst; Kinghorn Cancer Centre/Garvan Institute of Medical Research; NHMRC CTC; AGITG

Eligibility:

Men or women enrolled in the Australian Pancreatic Cancer Genome Initiative (APGI) who have confirmed adenocarcinoma of the pancreas that has recurred or metastasised and who have an eligible tumour molecular signature confirmed via genomic sequencing and protein expression. Patients should not have received prior treatment for metastatic disease.

Registration ID:

ACTRN12612000777897

Participation:

Australia

Australian Lead Group:

AGITG

Status:

Closed

Activation Date:

13/06/13

Chairs:

Andrew Biankin and John Simes (AU) Coordinating Investigator: Lorraine Chantrill

Contact:

impact.study@sydney.edu.au